Cutler Investment Counsel LLC Purchases 1,063 Shares of Becton, Dickinson and Company (BDX)

Cutler Investment Counsel LLC grew its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 53,847 shares of the medical instruments supplier’s stock after buying an additional 1,063 shares during the period. Becton, Dickinson and accounts for 2.5% of Cutler Investment Counsel LLC’s investment portfolio, making the stock its 13th largest position. Cutler Investment Counsel LLC’s holdings in Becton, Dickinson and were worth $10,551,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. lifted its holdings in Becton, Dickinson and by 2,427.8% during the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after purchasing an additional 15,887,611 shares in the last quarter. Koch Industries Inc. lifted its holdings in Becton, Dickinson and by 45,268.7% during the 2nd quarter. Koch Industries Inc. now owns 1,398,264 shares of the medical instruments supplier’s stock worth $1,391,000 after purchasing an additional 1,395,182 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Becton, Dickinson and by 8.5% during the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock worth $3,366,809,000 after purchasing an additional 1,353,780 shares in the last quarter. Winslow Capital Management LLC purchased a new stake in Becton, Dickinson and during the 2nd quarter worth about $225,164,000. Finally, Janus Henderson Group PLC lifted its holdings in Becton, Dickinson and by 1,265.9% during the 2nd quarter. Janus Henderson Group PLC now owns 1,210,837 shares of the medical instruments supplier’s stock worth $236,245,000 after purchasing an additional 1,122,191 shares in the last quarter. 87.91% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Becton, Dickinson and Company (NYSE:BDX) traded down $1.21 during trading on Monday, hitting $220.31. The stock had a trading volume of 719,600 shares, compared to its average volume of 1,325,275. The company has a debt-to-equity ratio of 1.48, a current ratio of 5.56 and a quick ratio of 5.01. The company has a market cap of $50,130.00, a price-to-earnings ratio of 23.22, a PEG ratio of 1.73 and a beta of 1.04. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $225.23.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, beating the consensus estimate of $2.37 by $0.03. The firm had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.14 billion. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. The company’s revenue was down 2.0% on a year-over-year basis. During the same period in the prior year, the company earned $2.12 EPS. analysts expect that Becton, Dickinson and Company will post 10.63 EPS for the current year.

In related news, EVP Linda M. Tharby sold 4,695 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $200.48, for a total transaction of $941,253.60. Following the transaction, the executive vice president now directly owns 18,670 shares in the company, valued at approximately $3,742,961.60. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Gary M. Cohen sold 15,512 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the transaction, the insider now owns 95,781 shares in the company, valued at $19,517,294.37. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 47,038 shares of company stock worth $9,480,225. 1.40% of the stock is owned by corporate insiders.

A number of brokerages recently issued reports on BDX. Barclays PLC reissued an “equal weight” rating and set a $210.00 price objective (up previously from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. BidaskClub lowered Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research upgraded Becton, Dickinson and from a “sell” rating to a “hold” rating in a research note on Friday, October 20th. Stifel Nicolaus restated a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $213.00 target price on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Five equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $214.79.

ILLEGAL ACTIVITY NOTICE: This article was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://stocknewstimes.com/2017/11/20/cutler-investment-counsel-llc-purchases-1063-shares-of-becton-dickinson-and-company-bdx.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply